Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 6/20 | 0.49 |
| ▸ | CA12 | O43570 | 5/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.49 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.49 |
| ▸ | SORD | Q00796 | 1/20 | 0.49 |
| ▸ | NQO1 | P15559 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 6/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.44 |
| ▸ | GABRD | O14764 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20420779 | 0.89 | CA12 (0.53) | CA9CA12AKR1B1MAOBMAOA | |
| SCHEMBL20420715 | 0.89 | CA12 (0.49) | CA9CA12AKR1B1MAOBMAOA | |
| SCHEMBL20420799 | 0.89 | CA12 (0.49) | CA9CA12AKR1B1MAOBMAOA | |
| SCHEMBL20420801 | 0.86 | HPGD (0.51) | MAOAHPGDCYP1B1SMN1; SMN2NPC1 | |
| SCHEMBL20420786 | 0.85 | ALDH1A1 (0.52) | MAOBMAOACA1HPGDSMN1; SMN2 | |
| SCHEMBL20428397 | 0.85 | ALDH1A1 (0.52) | CA9CA12AKR1B1MAOBMAOA | |
| SCHEMBL20420774 | 0.84 | PTGS2 (0.44) | CA9CA12NQO1CA1 | |
| SCHEMBL20420760 | 0.82 | CA12 (0.53) | CA9CA12AKR1B1MAOBMAOA | |
| SCHEMBL31264770 | 0.82 | CA9 (0.68) | CA9CA12AKR1B1MAOBMAOA | |
| SCHEMBL516275 | 0.82 | CA9 (0.68) | CA9CA12AKR1B1MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3354648-B1 | 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | CHENGDU ZENITAR BIOMEDICAL TECH CO LTD (CN) | 2022-04-06 | — | — | EP | disclosed |
| CN-108349959-B | 4-substituted coumarin derivative and preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2021-11-16 | — | — | CN | disclosed |
| US-10544134-B2 | 4-substituted coumarin derivatives and preparation methods and uses thereof | GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) | 2020-01-28 | — | — | US | disclosed |
| US-10544134-B2 | 4-substituted coumarin derivatives and preparation methods and uses thereof | GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) | 2020-01-28 | — | — | US | disclosed |
| US-20180282315-A1 | 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF | CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2018-10-04 | — | — | US | disclosed |
| EP-3354648-A1 | 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | Guizhou Bailing Group Pharmaceutical Co., Ltd. (CN) | 2018-08-01 | — | — | EP | disclosed |
| EP-3354648-A1 | 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | Guizhou Bailing Group Pharmaceutical Co., Ltd. (CN) | 2018-08-01 | — | — | EP | disclosed |
| CN-108349959-A | The coumarin derivative and its preparation method and application of 4 substitutions | 贵州百灵企业集团制药股份有限公司 | 2018-07-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544134-B2 | 4-substituted coumarin derivatives and preparation methods and uses thereof | MAP4, TUBA3C, ABCC1 | CA9 2723/4885CA12 3561/4885AKR1B1 599/4885 |
| US-20180282315-A1 | 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF | MAP4, TUBA3C, ABCC1 | CA9 2723/4885CA12 3561/4885AKR1B1 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.